Respiratory AIT Portfolio

About ALK Abello

ALK Abello is a century-old Danish specialty pharmaceutical company focused on allergy solutions, operating as a global leader in allergy immunotherapy with a comprehensive pipeline spanning respiratory allergies, food allergies, anaphylaxis, and adjacent therapy areas. The company has pioneered breakthrough technologies including sublingual immunotherapy tablets and is developing next-generation treatments like EURneffy, a needle-free anaphylaxis treatment. With their 'Allergy+' strategy for 2024-2028, ALK aims to leverage cutting-edge AI and digital innovation to accelerate drug discovery and help more people with more solutions more efficiently.

Therapeutic Areas